WOYZEK® Nicotine Inhaler Is Going To Sink Big Ships
For the first time Buchberger Laboratories Austria is releasing detailed information on its most promising pharmaceutical product candidate - the WOYZEK® Nicotine Inhaler - a cigarette smoking cessation aid for medium and long-term use.
Online, June 2, 2010 (Newswire.com) - The WOYZEK® inhaler is a clean pharmaceutical product developed entirely in Austria. WOYZEK®'s pharmacokinetic action - absorption of nicotine in pulmonary alveoli and transport to the brain - is impressive. The sensory and pharmacokinetic effects are so close to the cigarette that some blindfolded smokers may be unable to distinguish their usual cigarette brands.
Drugs and therapies currently available for smoking cessation show rather disappointing efficacies. 80-90% of cigarette smokers who attempt to quit fail eventually when applying available drugs and therapies. The WOYZEK® inhaler is particularly addressing this group of smokers. Cigarette smokers are asking for rapid nicotine delivery. WOYZEK® is providing this together with all other sensory effects of cigarettes. The WOYZEK® inhaler will boost the abstinence rate far above the 50 percent mark.
Buchberger Laboratories Austria, the company that has developed the WOYZEK® inhaler, is looking for corporate partners and investors who want to join bringing the inhaler to market.
Dr. H.M. Buchberger, Founder of Buchberger Laboratories: "There has never been a product so close to the cigarette reassembling tobacco smoke and its effects so impressively as the WOYZEK® inhaler. We have developed the inhaler and we have patented the technology. Now let us sink big ships!"
Find more detailed info at www.woyzek.com
Contact Person:
Dr. Helmut Buchberger, Managing Director
Phone: +46 8 501 64 512